Medical treatment of recurrent meningiomas

References

• Central Brain Tumor Registry of the USA. Statistical Report: Primary Brain Tumors in the United States, 2004–2006. Central Brain Tumor Registry of the USA, IL, USA (2010).
   Google Scholar
• Modan B, Baidatz D, Mart H, Steinitz R, Levin SG. Radiation-induced head and neck tumours. Lancet1, 277–279 (1974).
   PubMed Web of Science ®Google Scholar
• Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I. Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat. Res.163(4), 424–432 (2005).
   PubMed Web of Science ®Google Scholar
• Ron E, Preston DL, Mabuchi K, Thompson DE, Soda M. Cancer incidence in atomic bomb survivors. Part IV: comparison of cancer incidence and mortality. Radiat. Res.137(2 Suppl.), S98–S112 (1994).
   PubMed Web of Science ®Google Scholar
• Shintani T, Hayakawa N, Hoshi M et al. High incidence of meningioma among Hiroshima atomic bomb survivors. J. Radiat. Res. (Tokyo)40(1), 49–57 (1999).
   PubMedGoogle Scholar
• Ron E, Modan B, Boice JD Jr et al. Tumors of the brain and nervous system after radiotherapy in childhood. N. Engl. J. Med.319(16), 1033–1039 (1988).
   PubMed Web of Science ®Google Scholar
• Longstreth WT Jr, Phillips LE, Drangsholt M et al. Dental X-rays and the risk of intracranial meningioma: a population-based case–control study. Cancer100(5), 1026–34 (2004).
   PubMed Web of Science ®Google Scholar
• Claus EB, Black PM, Bondy M et al. Exogenous hormones and meningioma risk: what do we tell our patients? Cancer110(3), 471–476 (2007).
   PubMed Web of Science ®Google Scholar
• Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer6, 152 (200).
   Google Scholar
• Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F. Association of meningioma with reproductive factors. Int. J. Cancer119(5), 1152–1157 (2006).
   PubMed Web of Science ®Google Scholar
• Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am. J. Epidemiol.164(7), 629–636 (2006).
   PubMed Web of Science ®Google Scholar
• Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J. Neurooncol.99, 307–318 (2010).
   PubMed Web of Science ®Google Scholar
• Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J. Neurooncol.99(3), 307–314 (2010).
   PubMed Web of Science ®Google Scholar
• Lee Y, Liu J, Patel S et al. Genomic landscape of meningiomas. Brain Pathol.20(4), 751–62 (2010).
   PubMed Web of Science ®Google Scholar
• Perez-Magan E, Rodriquez de Lopez A, Ribalta T et al. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol.12(12), 1278–1290 (2010).
   PubMedGoogle Scholar
• Goldsmith B, McDermott MW. Meningioma. Neurosurg. Clin. N. Am.17, 111–120, vi (2006).
   PubMed Web of Science ®Google Scholar
• McMullen KP, Stieber VW. Meningioma: current treatment options and future directions. Curr. Treat. Options Oncol.5, 499–509 (2004).
   PubMedGoogle Scholar
• Ragel B, Jensen RL. New approaches for the treatment of refractory meningiomas. Cancer Control.10, 148–158 (2003).
   PubMedGoogle Scholar
• Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J. Neurooncol.99(3), 365–378 (2006).
   Google Scholar
• Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. Lancet363, 1535–1543 (2004).
   PubMed Web of Science ®Google Scholar
• Rogers L, Mehta M. Role of radiation therapy in treating intracranial meningiomas. Neurosurg. Focus23(4), E4 (2007).
   PubMedGoogle Scholar
• Elia AE, Shih HA, Loeffler JS. Stereotactic radiation treatment for benign meningiomas. Neurosurg. Focus23(4), E5 (2007).
   PubMedGoogle Scholar
• Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr. Neurol. Neurosci. Rep.9(3), 231–40 (2009).
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Wells M, Russell CA et al. Long term administration of mifreprisone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest.24(8), 727–33 (2006).
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Weiss M. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J. Neurooncol.8, 61–65 (1990).
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Rankin C, Townsend J et al. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc. Am. Soc. Clin. Oncol.20, 56a (2001) (Abstract 222).
   Google Scholar
• Goodwin JW, Crowley J, Eyre HJ et al. A Phase II evaluation of tamoxifen unresectable or refractory meningiomas: a Southwest Oncology Group Study. J. Neurooncol.15, 73–77 (1993).
   Google Scholar
• McCutcheon IE, Flyvbjerg A, Hill H et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J. Neurosurg.94, 487–492 (2001).
   PubMed Web of Science ®Google Scholar
• Kaba SE, DeMonte F, Bruner JM et al. The treatment of recurrent unresectable and malignant meningiomas with interferon α-2B. Neurosurg.40, 271–275 (1997).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ. α-interferon for recurrent WHO grade I intracranial meningiomas. Cancer113, 2146–2151 (2008).
   PubMed Web of Science ®Google Scholar
• Schrell UM, Ritting MG, Anders M et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J. Neurosurg.86(5), 845–852 (1997).
   PubMed Web of Science ®Google Scholar
• Schrell UM, Ritting MG, Anders M et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J. Neurosurg.86, 840–844 (1997).
   PubMed Web of Science ®Google Scholar
• Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br. J. Neurosurg.18, 495–499 (2004).
   PubMed Web of Science ®Google Scholar
• Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J. Neurooncol.49(2), 165–170 (2004).
   Google Scholar
• Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J. Neurosurg.97, 341–346 (2002).
   PubMed Web of Science ®Google Scholar
• Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J. Clin. Neurosci.9(2), 156–158 (2002).
   PubMed Web of Science ®Google Scholar
• Hahn BM, Schrell UMH, Sauer R et al. Prolonged oral hydroxyurea and concurrent 3f-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J. Neurooncol.74, 157–165 (2005).
   PubMed Web of Science ®Google Scholar
• Loven D, Hardoff R, Sever ZB et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J. Neurooncol.67, 221–226 (2004).
   PubMed Web of Science ®Google Scholar
• Swinnen LJ, Renkin C, Rushing EJ et al. Phase 2 study of hydroxyurea for unresectable meningioma (Southwest Oncology group S9811). Proc. Am. Soc. Clin. Oncol.27, 102s (2009) (Abstract 2063).
   Google Scholar
• Chamberlain MC, Johnston SA. Hydroxyurea for recurrent surgery and radiation refractory meningioma. Neuro Oncol.12(Suppl. 4), iv36–iv57 (2010) (Abstract OT-04).
   Google Scholar
• Ragel BT, Couldwell WT, Wurster RD, Jensen RL. Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas. Neurosurg. Focus23(4), E10 (2007).
   PubMedGoogle Scholar
• Chamberlain MC, Tsao-Wei D, Groshen S. Temozolomide for treatment resistant recurrent meningioma. Neurology62(7), 1210–1212 (2004).
   PubMed Web of Science ®Google Scholar
• Gupta V, Su YS, Samuelson CG et al. CPT-11: a potential new chemotherapy for atypical or malignant meningiomas. J. Neurosurg.106(3), 455–462 (2007).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Tsao-Wei D, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J. Neurooncol.78(3), 271–276 (2006).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Malignant meningiomas: adjunct combined modality therapy. J. Neurosurg.84, 733–736 (1996).
   PubMed Web of Science ®Google Scholar
• Hanft S, Canoll P, Bruce JN. A review of malignant meningioma: diagnosis, characteristics, and treatment. J. Neurooncol.99(3), 433–443 (2010).
   PubMed Web of Science ®Google Scholar
• Johnson M, Toms S. Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J. Neuropathol. Exp. Neurol.64, 1029–1036 (2005).
   PubMed Web of Science ®Google Scholar
• Ragel BT, Jensen RL. Aberrant signaling pathways in meningiomas. J. Neurooncol.99(3), 315–324 (2010).
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WK, Lamborn KR et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin. Cancer Res12, 4899–4907 (2006).
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WKA, Lamborn KR et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01–08). Neuro Oncol.11(6), 853–860 (2009).
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Abrey LE, Lassman AB et al. A Phase I trial of erlotinib in patients with non-progressive glioblastoma multiforme post-radiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol12(1), 87–94 (2010).
   PubMed Web of Science ®Google Scholar
• Crombet T. Torres O. Rodriguez V et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma20, 131–136 (2001).
   PubMed Web of Science ®Google Scholar
• Arena S, Barbieri F, Thellung S et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J. Neurooncol.66, 155–166 (2004).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with Sandostatin. Neurology69, 969–973 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson DR, Kimmel DW, Burch PA et al. Phase II study of octreotide in recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol12(Suppl. 4), iv36–iv57 (2010) (Abstract OT-24).
   Google Scholar
• Hammond S, Norden A, Drappatz J et al. Phase II study of monthly pasireotide LAR (SOM230c) for recurrent or progressive meningioma. Neuro Oncol.12(Suppl. 4), iv69–iv68 (2010) (Abstract OT-12).
   Google Scholar
• Kaley TJ, Wen PY, Schiff D et al. Phase II trial of sunitinib (SU011248) for recurrent meningioma. Neuro Oncol.12(Suppl. 4), iv69–iv68 (2010) (Abstract OT-27).
   Google Scholar
• Raizer J, Grimm S, Chandler J et al. A Phase II study trial of PTK787/ZK 222584 (PTK787) in recurrent or progressive meningiomas. Neuro Oncol.12(Suppl. 4), iv36–iv57 (2010) (Abstract NO-62).
   Google Scholar